user

An audit of thromboprophylaxis for patients with myeloma on the immunomodulatory therapies: thalidomide, lenalidomide or pomalidomide

被引：0
|
作者：
Melly, M. [1 ]
Al-Talib, M. [1 ]
机构：
[1] North Bristol NHS Trust, Bristol, Avon, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2018年 / 181卷
关键词：
immunomodulatory drugs; lenalidomide; myeloma; pomalidomide; thalidomide; thromboprophylaxis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH18-EP-0
引用
收藏
页码：186 / 186
页数：1
相关论文
共 50 条
  • [1] Treatment of multiple myeloma with immunomodulatory drugs - thalidomide, lenalidomide and pomalidomide
    Rzepecki, Piotr
    [J]. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2009, 13 (05): : 265 - 275
  • [2] Thromboprophylaxis In Multiple Myeloma Patients Undergoing Immunomodulatory Therapy with Thalidomide and Lenalidomide: A Systematic Review and Meta-Analysis
    Carrier, Marc
    Le Gal, Gregoire
    Tay, Jason
    Wu, Cynthia M.
    Lee, Agnes Y.
    [J]. BLOOD, 2010, 116 (21) : 475 - 476
  • [3] Audit of thromboprophylaxis for patients with multiple myeloma on treatment with immunomodulatory drugs
    Kumari, A.
    Man, R.
    Gardner, C.
    Paneesha, S.
    Kishore, B.
    Pratt, G.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 173 : 90 - 90
  • [4] Immunomodulatory Properties of Thalidomide Analogs: Pomalidomide and Lenalidomide, Experimental and Therapeutic Applications
    Bodera, Pawel
    Stankiewicz, Wanda
    [J]. RECENT PATENTS ON ENDOCRINE METABOLIC & IMMUNE DRUG DISCOVERY, 2011, 5 (03) : 192 - 196
  • [5] An audit on the use of lenalidomide in patients with myeloma
    Ladani, S.
    Barton, L.
    Garg, M.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 : 49 - 49
  • [6] Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens
    Storrar, Neill P. F.
    Mathur, Abhinav
    Johnson, Peter R. E.
    Roddie, P. Huw
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (01) : 142 - 144
  • [7] Thromboprophylaxis prescribing and thrombotic event rates in multiple myeloma patients treated with lenalidomide or thalidomide at a specialist cancer hospital
    Alexander, Marliese
    Teoh, Khai C.
    Lingaratnam, Senthil
    Kirsa, Sue
    Mellor, James D.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 (02) : 169 - 175
  • [8] Effect of Immediate Prior-Line Lenalidomide or Thalidomide Therapy on Response To Pomalidomide In Multiple Myeloma
    Hwa, Yi Lisa
    Laumann, Kristina M.
    LaPlant, Betsy R.
    Buadi, Francis
    Dingli, David
    Dispenzieri, Angela
    Gertz, Morie A.
    Go, Ronald S.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Kumar, Shaji K.
    Leung, Nelson
    Lin, Yi
    Lust, John A.
    McCurdy, Arleigh
    Mikhael, Joseph
    Roy, Vivek
    Russell, Stephen
    Zeldenrust, Steven R.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    [J]. BLOOD, 2013, 122 (21)
  • [9] Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma
    Zhu, Yuan Xiao
    Kortuem, K. Martin
    Stewart, A. Keith
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (04) : 683 - 687
  • [10] DIARRHEA INCIDENCE IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE AND POMALIDOMIDE
    Capecchi, M.
    Corradini, P.
    Montefusco, V.
    [J]. HAEMATOLOGICA, 2016, 101 : 795 - 796
12345